Third, for ethical reasons, there are no randomized controlled tests; therefore, the quality of evidence from cohort studies could provide clinicians and pregnant women with a research in medical practice. You will find limitations in our meta-analysis related to evidence synthesis and quality. Table S6. Exposure to fluoxetine during the 1st trimester of pregnancy and risk of congenital malformations in babies: results of meta-analyses. Table S7. Exposure to paroxetine during the 1st trimester of pregnancy and risk of congenital malformations in babies: results of meta-analyses. Table S8. Exposure to sertraline during the 1st trimester of pregnancy and risk of congenital malformations in babies: results of meta-analyses. Table S9. Exposure to escitalopram during the 1st trimester of pregnancy and risk of congenital malformations in babies: results of meta-analyses. Table S10. Exposure to fluvoxamine during the 1st trimester of pregnancy and risk of congenital malformations in babies: results of meta-analyses. Table S11. Subgroup analysis of selective serotonin reuptake inhibitors PSI (SSRIs) and risk of congenital malformations in babies: results of meta-analyses. Table S12. Subgroup analysis of citalopram and risk of congenital malformations in babies: results of meta-analyses. Table S13. Subgroup analysis of fluoxetine and risk of congenital malformations in babies: results of meta-analyses. Table S14. Subgroup analysis of paroxetine and risk of congenital malformations in babies: results of meta-analyses. Table S15. Subgroup analysis of sertraline and risk of congenital malformations in babies: results of meta-analyses. (DOC 1162?kb) 12916_2018_1193_MOESM3_ESM.doc (1.1M) GUID:?8F553D80-87B7-46F7-B6A6-DF11805272AA Additional file 4: Number S1. Risk of major congenital anomalies in babies, relating to maternal exposure to citalopram. (TIF 1083?kb) 12916_2018_1193_MOESM4_ESM.tif (1.0M) GUID:?FDD821C0-33FE-47F8-90CF-31CB3804FBAB Additional file 5: Number S2. Risk of congenital heart defects in babies, relating to maternal exposure to citalopram. (TIF 1123?kb) 12916_2018_1193_MOESM5_ESM.tif (1.0M) GUID:?BE4E170B-DF69-49EE-BCF9-224B2E1118AB Additional file 6: Number S3. Risk of major congenital anomalies in babies, relating to maternal exposure to fluoxetine. (TIF 1141?kb) 12916_2018_1193_MOESM6_ESM.tif (1.1M) GUID:?4F90C6F5-AA81-4913-B7DF-1CCA248C4A13 Additional file 7: Figure S4. Risk of congenital heart defects in babies, relating to maternal exposure to fluoxetine. (TIF 1177?kb) 12916_2018_1193_MOESM7_ESM.tif (1.1M) GUID:?CCC3A246-F532-4EA4-910F-F74A4AED0C19 Additional file 8: Figure S5. Risk of major congenital anomalies in babies, relating to maternal exposure to paroxetine. (TIF 1135?kb) 12916_2018_1193_MOESM8_ESM.tif (1.1M) GUID:?C5BE0B00-E5FD-46FB-9411-3E58D62DB665 Additional file 9: Figure S6. Risk of congenital heart defects in babies, relating to maternal exposure to paroxetine. (TIF 1244?kb) 12916_2018_1193_MOESM9_ESM.tif (1.2M) GUID:?FFBAEE82-CACA-4CC0-AC82-54C70C4B15CC Additional file 10: Figure S7. Risk of major congenital anomalies in babies, relating to maternal exposure to sertraline. (TIF 1112?kb) 12916_2018_1193_MOESM10_ESM.tif (1.0M) GUID:?44849109-F864-4FAC-9EAF-B7ED77EC430A Additional file 11: Figure S8. Risk of congenital heart defects in babies, relating to maternal exposure to sertraline. (TIF 1185?kb) 12916_2018_1193_MOESM11_ESM.tif (1.1M) GUID:?801D283E-5A1B-4E99-B1D3-9B8F614324EB Data Availability StatementThe datasets used and/or analyzed during the current study are available from your corresponding author about reasonable request. Abstract Background In 2005, the FDA cautioned that exposure to paroxetine, a selective serotonin reuptake inhibitor (SSRI), during the 1st trimester of PSI pregnancy may increase the risk of cardiac malformations. Since then, the association between maternal use of SSRIs during pregnancy and congenital malformations in babies has been the subject of much conversation and controversy. The aim of this study is definitely to systematically review the associations between SSRIs use during early pregnancy and the risk of congenital malformations, with particular attention to the potential confounding by indicator. Methods The study protocol was authorized with PROSPERO (CRD42018088358). Cohort studies on congenital malformations in babies Mouse monoclonal to CD235.TBR2 monoclonal reactes with CD235, Glycophorins A, which is major sialoglycoproteins of the human erythrocyte membrane. Glycophorins A is a transmembrane dimeric complex of 31 kDa with caboxyterminal ends extending into the cytoplasm of red cells. CD235 antigen is expressed on human red blood cells, normoblasts and erythroid precursor cells. It is also found on erythroid leukemias and some megakaryoblastic leukemias. This antobody is useful in studies of human erythroid-lineage cell development born to mothers with first-trimester exposure to SSRIs were recognized via PubMed, PSI Embase, Web of Science, and the Cochrane Library databases through 17 January 2018. Random-effects models were used to calculate summary relative risks (RRs). Results Twenty-nine cohort studies including 9,085,954 births were identified. Overall, use of SSRIs was associated with an increased risk of overall major congenital anomalies (MCAs, RR 1.11, 95% CI 1.03 to 1 1.19) and congenital heart problems (CHD, RR 1.24, 95% CI 1.11 to 1 1.37). No significantly improved risk was observed when restricted to women having a psychiatric analysis (MCAs, RR 1.04, 95% CI 0.95 to 1 1.13; CHD, RR 1.06, 95% CI 0.90 to 1 1.26). Related significant associations were observed using maternal citalopram exposure (MCAs, RR 1.20, 95% CI 1.09 to 1 1.31; CHD, RR 1.24, 95% CI 1.02 to 1 1.51), fluoxetine (MCAs, RR.